Premium
First trimester maternal serum placental growth factor in trisomy 21 pregnancies
Author(s) -
Cowans N. J.,
Stamatopoulou A.,
Spencer K.
Publication year - 2010
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.2496
Subject(s) - trisomy , placental growth factor , medicine , aneuploidy , obstetrics , down syndrome , pregnancy , pregnancy associated plasma protein a , first trimester , second trimester , gynecology , andrology , fetus , biology , genetics , chromosome , psychiatry , gene , vascular endothelial growth factor , vegf receptors
Objective To examine placental growth factor (PlGF) levels in first trimester maternal serum in trisomy 21 pregnancies and to investigate the potential value of PlGF in a first trimester screening test. Methods First trimester maternal serum from 70 trisomy 21 cases and 375 euploid controls were retrospectively analyzed for PlGF using a DELFIA ® Xpress immunoassay platform. Results were expressed as multiples of medians (MoM) for comparison. Results PlGF levels were significantly decreased in pregnancies with trisomy 21, 0.76 MoM versus 0.98 MoM in controls. Inclusion of PlGF into the first trimester combined test [maternal age, pregnancy associated plasma protein‐A (PAPP‐A), free‐β human chorionic gonadotrophin (β‐hCG) and nuchal translucency] would increase the detection rate by 0.5% at a 5% false positive rate. Conclusion PlGF at 11 weeks to 13 weeks 6 days has the potential to be included as a marker for the detection of pregnancies with trisomy 21. Copyright © 2010 John Wiley & Sons, Ltd.